Welcome to MediciNova
MediciNova Analyst/Investor Meeting in New York City, on Wednesday July 9, 2008 at 8:00AM (Eastern)
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova’s current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, an acute, severe asthma attack, and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points.
Clinical Trial Update: MN-221
June 23, 2008 - MediciNova Initiates Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
March 31, 2008 - MediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
Clinical Trial Update: MN-166
April 7, 2008 - MediciNova Reports Clinical Results from Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
- MN-166 Slows Disability Progression; Significant Neuroprotective Effects Observed by MRI -
